Drug Profile
Nivolumab biosimilar - Amgen
Alternative Names: ABP-206Latest Information Update: 20 Oct 2023
Price :
$50
*
At a glance
- Originator Amgen
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Malignant melanoma
Most Recent Events
- 26 Sep 2023 Amgen plans a phase III trial for Malignant melanoma (Metastatic, Inoperable/Unresectable, First-line therapy, Late-stage disease) (IV, Infusion) in October 2023 (NCT06054555; EudraCT2023-503288-40)
- 20 Sep 2023 Phase-III clinical trials in Malignant melanoma (Metastatic disease, Inoperable/Unresectable, First-line therapy, Late-stage disease) in Canada, Georgia, Spain, USA (IV) (NCT06054555)
- 26 Jul 2023 Phase-III clinical trials in Malignant melanoma (Late-stage disease) in Israel (IV) (NCT05907122) (Amgen pipeline, August 2023)